Approval · Notice of Compliance 16366 · 2014
SILDENAFIL: Notice of Compliance 16366
Issued November 26, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16366
- Date
- November 26, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Addeitional product name
- Therapeutic class
- Cgmp-specific phosphodiesterase type 5 inhibitor - treatment of erectil dysfunction
- Canadian reference product
- VIAGRA (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SILDENAFIL | 02433303 | Cancelled Pre Market |
| SILDENAFIL | 02433311 | Cancelled Pre Market |
| SILDENAFIL | 02433338 | Cancelled Pre Market |
Medicinal ingredients
- SILDENAFIL CITRATE 25 MG per TAB
- SILDENAFIL CITRATE 50 MG per TAB
- SILDENAFIL CITRATE 100 MG per TAB